These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12090747)

  • 1. Continuous multilead ST-monitoring identifies patients with unstable coronary artery disease who benefit from extended antithrombotic treatment.
    Jernberg T; Abrahamsson P; Lindahl B; Johanson P; Wallentin L; Dellborg M
    Eur Heart J; 2002 Jul; 23(14):1093-101. PubMed ID: 12090747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
    Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving outcomes in acute coronary syndromes--the FRISC II trial.
    Kontny F
    Clin Cardiol; 2001 Mar; 24(3 Suppl):I3-7. PubMed ID: 11286312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial.
    Wallentin L
    Haemostasis; 2000; 30 Suppl 2():108-13; discussion 106-7. PubMed ID: 11251353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators.
    Lancet; 1999 Aug; 354(9180):701-7. PubMed ID: 10475180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients.
    Akkerhuis KM; Klootwijk PA; Lindeboom W; Umans VA; Meij S; Kint PP; Simoons ML
    Eur Heart J; 2001 Nov; 22(21):1997-2006. PubMed ID: 11603907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC).
    Klein W; Buchwald A; Hillis SE; Monrad S; Sanz G; Turpie AG; van der Meer J; Olaisson E; Undeland S; Ludwig K
    Circulation; 1997 Jul; 96(1):61-8. PubMed ID: 9236418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group.
    Lindahl B; Venge P; Wallentin L
    J Am Coll Cardiol; 1997 Jan; 29(1):43-8. PubMed ID: 8996293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
    Husted S; Kher A
    Ann Med; 2000 Dec; 32 Suppl 1():53-9. PubMed ID: 11209983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group.
    Swahn E; Wallentin L
    Am J Cardiol; 1997 Sep; 80(5A):25E-29E. PubMed ID: 9296466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization.
    Husted SE; Wallentin L; Lagerqvist B; Kontny F; Ståhle E; Swahn E
    Eur Heart J; 2002 Aug; 23(15):1213-8. PubMed ID: 12127923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators.
    Lancet; 1999 Aug; 354(9180):708-15. PubMed ID: 10475181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study).
    Wallentin L; Husted S; Kontny F; Swahn E
    Am J Cardiol; 1997 Sep; 80(5A):61E-63E. PubMed ID: 9296473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A critical review of clinical trials for low-molecular-weight heparin therapy in unstable coronary artery disease.
    Husted S; Becker R; Kher A
    Clin Cardiol; 2001 Jul; 24(7):492-9. PubMed ID: 11444639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial.
    Janzon M; Levin LA; Swahn E;
    Heart; 2003 Mar; 89(3):287-92. PubMed ID: 12591833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative contributions of a single-admission 12-lead electrocardiogram and early 24-hour continuous electrocardiographic monitoring for early risk stratification in patients with unstable coronary artery disease.
    Holmvang L; Andersen K; Dellborg M; Clemmensen P; Wagner G; Grande P; Abrahamsson P
    Am J Cardiol; 1999 Mar; 83(5):667-74. PubMed ID: 10080416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ischaemia detected by continuous on-line vectorcardiographic monitoring predicts unfavourable outcome in patients admitted with probable unstable coronary disease.
    Andersen K; Eriksson P; Dellborg M
    Coron Artery Dis; 1996 Oct; 7(10):753-60. PubMed ID: 8970766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prognostic information from continuous ST segment monitoring. TRIM study group. Thrombin Inhibition in Myocardial Ischemia.
    Nørgaard BL; Andersen K; Dellborg M; Abrahamsson P; Ravkilde J; Thygesen K
    J Am Coll Cardiol; 1999 May; 33(6):1519-27. PubMed ID: 10334417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease.
    Oldgren J; Fellenius C; Boman K; Jansson JH; Nilsson TK; Wallentin L; Siegbahn A
    J Intern Med; 2005 Nov; 258(5):420-7. PubMed ID: 16238677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy.
    Goodman SG; Barr A; Sobtchouk A; Cohen M; Fromell GJ; Laperrière L; Hill C; Langer A
    J Am Coll Cardiol; 2000 Nov; 36(5):1507-13. PubMed ID: 11079650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.